Compare ACADIA Pharmaceuticals Inc. (ACAD) vs S&P Global Inc (SPGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs S&P Global Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while S&P Global Inc trades at $432.88 (market cap $131.26B). The key difference: S&P Global Inc is far larger — about 29.2× ACADIA Pharmaceuticals Inc.'s market cap, and S&P Global Inc pays a 0.87% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SPGI | |
|---|---|---|
Market Cap | $4.49B | $131.26B |
Sector | Health | Financials |
52-Week High | $28.06 | $534.79 |
52-Week Low | $20.06 | $370.42 |
Enterprise Value | $3.69B | $143.23B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
S&P Global (SPGI) trades at $443.46, up 0.81% with strong bullish momentum. The stock shows robust fundamentals with 29.15% net margin and consistent earnings beats in three of the last four quarters. Recent completion of Mobility Global spinoff and AI-driven market intelligence initiatives position the company for growth. Technical indicators show bullish moving averages while RSI suggests potential overbought conditions near-term.
Outlook remains positive with 85.7% analyst buy ratings and $533.50 consensus target implying 20% upside. Key risks include interest rate sensitivity in credit rating segment and execution of AI transformation. The company's subscription-based revenue model and market data dominance provide stable cash flow foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
